Biophore India gets DCGI nod to manufacture Covid-19

  • Post comments:0 Comments
Biophore India gets DCGI nod to manufacture Covid-19

Hyderabad based Biophore India gets DCGI to manufacture Favipiravir , a drug used in the finished formulation to treat mild to moderate cases of Covid-19. Favipiravir is an antiviral agent that was initially discovered and developed because of its activity against another RNA (ribonucleic acid) virus, the influenza virus.

Besides DCGI’s nod to produce the active pharmaceutical ingredient in India, it has been cleared for exports as well. It also received approval in Turkey to export the API in collaboration with a local partner and additionally, the company is in talks with several Indian partners to commercialize the product in India and with Bangladesh and Egypt-based companies for its export, Biophore India said.

Leave a Reply